Literature DB >> 12652354

Post-challenge hyperglycaemia is associated with premature death and macrovascular complications.

Q Qiao1, J Tuomilehto, K Borch-Johnsen.   

Abstract

Unravelling the precise association between cardiovascular disease and Type II (non-insulin-dependent) diabetes mellitus has proved problematic, largely as a result of the confusing variety of diagnostic criteria and methodologies used in previous studies of disease-associated risk. More recently, improved standardization and continuing refinements to risk analyses have begun to clarify the relative importance of individual risk factors for macrovascular complications and progression to cardiovascular disease. The evidence accumulated from several large-scale epidemiological and intervention studies strongly indicates that hyperglycaemia and specifically the post-load hyperglycaemia resulting from postprandial glucose excursions is the main factor associated with increasing the risks of morbidity and mortality in Type II diabetes. The DECODE study has de-emphasized the importance of fasting glucose, in contrast to post-load hyperglycaemia, as the principal measurable determinant of exposure to the risk of cardiovascular disease in Type II diabetes. Similarly, the Diabetes Intervention Study identified mealtime hyperglycaemia as an independent risk factor for myocardial infarction and all-cause mortality, while several other studies have also shown that such mortality is better predicted from post-challenge measurement criteria rather than from fasting-glucose criteria. It is likely that postprandial hyperglycaemia is an independent risk factor for atherosclerosis and is also exerting an atherogenic effect indirectly through the clustering of a number of risk factors for atherosclerosis. Whether the relation between post-load hyperglycaemia and the risk of cardiovascular events is causal is still not known.

Entities:  

Mesh:

Year:  2002        PMID: 12652354     DOI: 10.1007/s00125-002-0932-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  19 in total

Review 1.  Best practice in primary care pathology: review 10.

Authors:  W S A Smellie; N Shaw; R Bowley; M F Stewart; A M Kelly; P J Twomey; P R Chadwick; J B Houghton; J P Ng; A J McCulloch
Journal:  J Clin Pathol       Date:  2007-05-11       Impact factor: 3.411

Review 2.  What are the best options for controlling prandial glycemia?

Authors:  Stephen Clement
Journal:  Curr Diab Rep       Date:  2009-10       Impact factor: 4.810

Review 3.  Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Authors:  Andrew J Krentz; Clifford J Bailey
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  [The importance of rehabilitation with cardiovascular diabetic patients after surgical interventions].

Authors:  S Jacob
Journal:  Clin Res Cardiol       Date:  2006-01       Impact factor: 5.460

5.  [Impairment of cardiac autonomic nervous system and incidence of arrhythmias in severe hyperglycemia].

Authors:  Sven Süfke; Hasib Djonlagić; Thomas Kibbel
Journal:  Med Klin (Munich)       Date:  2011-01-16

6.  Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data.

Authors:  T Kaiser; P T Sawicki
Journal:  Diabetologia       Date:  2004-01-16       Impact factor: 10.122

Review 7.  Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.

Authors:  Panai Song; Akira Onishi; Hermann Koepsell; Volker Vallon
Journal:  Expert Opin Ther Targets       Date:  2016-04-12       Impact factor: 6.902

Review 8.  Who should benefit from the use of alpha-glucosidase inhibitors?

Authors:  Ariane Godbout; Jean-Louis Chiasson
Journal:  Curr Diab Rep       Date:  2007-10       Impact factor: 4.810

9.  Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men.

Authors:  M S Lewitt; A Hilding; C-G Ostenson; S Efendic; K Brismar; K Hall
Journal:  Diabetologia       Date:  2008-05-22       Impact factor: 10.122

10.  Three years follow-up of screen-detected diabetic and non-diabetic subjects: who is better off? The ADDITION Netherlands study.

Authors:  Paul G H Janssen; Kees J Gorter; Ronald P Stolk; Mehmet Akarsubasi; Guy E H M Rutten
Journal:  BMC Fam Pract       Date:  2008-12-16       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.